Department of Medicine, Division of Gastroenterology, Cooper University Health Care, Camden, New Jersey, USA.
Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Drugs Today (Barc). 2020 Nov;56(11):715-721. doi: 10.1358/dot.2020.56.11.3202811.
Gastroesophageal reflux disease (GERD) is the most common upper gastrointestinal disorder in the United States. Although proton pump inhibitors (PPIs) are the mainstay of therapy for GERD and its complications, they have several limitations, including incomplete symptom resolution. Potassium-competitive acid blockers (P-CABs) were developed to address the limitations of PPIs as well as the need for improved antisecretory effects. Tegoprazan, the newest P-CAB, was approved in 2018 in South Korea for the treatment of erosive esophagitis (EE) and nonerosive reflux disease (NERD). A highly selective inhibitor of the H+/K+-ATPase, tegoprazan is also safe and effective for nocturnal acid breakthrough (NAB) and motility. Further studies of tegoprazan are warranted to define its potential role in the treatment of acid-related disorders.
胃食管反流病（GERD）是美国最常见的上消化道疾病。质子泵抑制剂（PPIs）虽然是 GERD 及其并发症治疗的主要方法，但存在一些局限性，包括症状缓解不完全。钾竞争酸阻滞剂（P-CAB）的开发是为了应对 PPI 的局限性以及对改善抗分泌作用的需求。替戈拉赞是最新的 P-CAB，于 2018 年在韩国获得批准，用于治疗糜烂性食管炎（EE）和非糜烂性反流病（NERD）。作为 H+/K+-ATPase 的高度选择性抑制剂，替戈拉赞对夜间酸突破（NAB）和动力也安全有效。进一步研究替戈拉赞对于确定其在酸相关疾病治疗中的潜在作用是有必要的。
